Covid-19 patients in one of the U.S.'s hardest hit areas—Arizona—now have increased access to a promising but underused experimental therapy that aims to keep them out of the hospital.
The Department of Health and Human Services announced Thursday the opening of a temporary center in Tucson, Ariz., to provide monoclonal antibody treatments on an outpatient basis to people infected with Covid-19.
The center at Tucson Medical Center marks the second such temporary center after the one was set up a week ago in Imperial County Calif. Arizona is averaging the highest number of infections per capita, with more than ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.